- Home
- BRY vs IMMP Comparison
BRY vs IMMP Comparison
Compare BRY & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- IMMP
- Stock Information
- Founded
- BRY 1909
- IMMP 1987
- Country
- BRY United States
- IMMP Australia
- Employees
- BRY N/A
- IMMP N/A
- Industry
- BRY Oil & Gas Production
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- IMMP Health Care
- Exchange
- BRY Nasdaq
- IMMP Nasdaq
- Market Cap
- BRY 186.1M
- IMMP 221.2M
- IPO Year
- BRY N/A
- IMMP N/A
- Fundamental
- Price
- BRY $2.91
- IMMP $1.65
- Analyst Decision
- BRY Buy
- IMMP Buy
- Analyst Count
- BRY 2
- IMMP 1
- Target Price
- BRY $5.00
- IMMP $7.00
- AVG Volume (30 Days)
- BRY 1.4M
- IMMP 103.0K
- Earning Date
- BRY 08-08-2025
- IMMP 02-27-2025
- Dividend Yield
- BRY 4.14%
- IMMP N/A
- EPS Growth
- BRY N/A
- IMMP N/A
- EPS
- BRY N/A
- IMMP N/A
- Revenue
- BRY $753,737,000.00
- IMMP $3,019,249.00
- Revenue This Year
- BRY N/A
- IMMP $50.37
- Revenue Next Year
- BRY $0.96
- IMMP N/A
- P/E Ratio
- BRY N/A
- IMMP N/A
- Revenue Growth
- BRY N/A
- IMMP 24.11
- 52 Week Low
- BRY $2.11
- IMMP $1.32
- 52 Week High
- BRY $7.02
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- BRY 52.12
- IMMP 44.20
- Support Level
- BRY $2.74
- IMMP $1.53
- Resistance Level
- BRY $2.90
- IMMP $1.67
- Average True Range (ATR)
- BRY 0.18
- IMMP 0.07
- MACD
- BRY -0.03
- IMMP -0.00
- Stochastic Oscillator
- BRY 30.43
- IMMP 35.37
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.